| All PsA n= 38 | Erosive PsA n= 29 | Nonerosive PsA n= 9 | Psoriasis alone n= 10 | Healthy control n= 12 |
---|---|---|---|---|---|
Female sex, n (%) | 16 (42%) | 11 (38%) | 5 (56%) | 4 (40%) | 11 (92%)b |
Age, years, median (range) | 50 (26-68) | 50 (26-63) | 47 (33-68) | 44 (19-72) | 48 (21-53) |
Caucasian ethnicity, n (%) | 32 (84%) | 25 (86%) | 7 (78%) | 7 (70%) | 10 (83%) |
Weight, kg, median (range) | 78 (32-116) | 80 (65-114) | 74 (32-116) | 82 (67.9-103) | 81 (46-109) |
Psoriasis disease duration, years, median (range) | 20 (0.5-50) | 20 (3-50) | 20 (0.5-40) | 18 (0.4-53) | NA |
Arthritis disease duration, years, median (range) | 10 (0.5-45) | 11 (5-33) | 5 (0.5-45) | NA | NA |
PASI, median (range) | 1.6 (0-12) | 1.5 (0-12) | 1.6 (1-3.4) | 13 (6.3-23.2)b | NA |
Nail score, median (range) | 7 (0-47) | 9 (0-47) | 6 (0-25) | 6 (0-25) | NA |
Creatinine, μmol/L, median (range) | 77 (23-249) | 78 (23-249) | 77 (42-89) | 76 (39-100) | NA |
C-reactive protein, mg/L, median (range) | 6.5 (1-59) | 7.2 (1-59) | 5.8 (1-26) | 2.6 (1-7.2)b | 2.1 (1-15)b |
DAS28-CRP, median (range) | 3.9 (1.4-6.6) | 4.2 (2.3-6.6) | 2.7 (1.4-6.0)a | NA | NA |
Methotrexate use, n (%) | 22 (58%) | 15 (52%) | 7 (78%) | 1 (10%)b | 0 (0)b |
Prednisone use, n (%) | 7 (18%) | 4 (14%) | 3 (33%) | 0 (0) | 0 (0) |
Nonsteroidal antiinflammatory drug use, n (%) | 19 (50%) | 16 (55%) | 3 (33%) | 0 (0)b | 0 (0)b |
Biologics use, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
XR erosion score, median (range) | 29 (0-183) | 43 (1-183) | 0 (0-0)a | NA | NA |
XR narrowing score, median (range) | 24.5 (0-160) | 36 (2-160) | 0 (0-10)a | NA | NA |
Combined XR score, median (range) | 59 (0-343) | 78 (3-343) | 0 (0-10)a | NA | NA |
Number of joints with pencil-in-cup deformities on XR, median (range) | 0 (0-17) | 0 (0-17) | 0 (0-0) | NA | NA |
Number of joints with new bone formation on XR, median (range) | 1 (0-9) | 1 (0-9) | 0 (0-7) | NA | NA |
Radiographic sacroiliitis, n (%) | 15 (39%) | 12 (41%) | 3 (33%) | NA | NA |
Total hip BMD T score, median (range) | -0.1 (-3.5-2.0) | -0.1 (-2.1-2.0) | -0.2 (-3.5-0.9) | NA | NA |